1. India Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Blue Jet Healthcare Limited

Blue Jet Healthcare Limited

BLUEJET.BO
Blue Jet Healthcare LimitedIN flagBombay Stock Exchange
623.35
INR
+48.55
- -
108.29BMarket Cap
Blue Jet Healthcare Limited
BLUEJET.BO
(Bombay Stock Exchange)

Recent

price

623.35

P/E

ratio

- -

div

yld

- -

ROIC.AI

2021
2022
2023
2024
2025
2026
TTM
FRC
28.58
39.11
41.54
40.95
59.36
54.63
70.45
Revenue per Share
7.98
10.47
9.23
9.44
17.59
14.29
20.68
Basic EPS, GAAP
4.62
7.12
4.74
3.86
-1.97
6.61
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
1
1.2
- -
Dividend per Share
19.04
30.07
39.29
48.73
65.31
2
- -
Book Value per Share
19.59
30.07
39.28
48.71
65.28
78.29
- -
Tangible Book Value per Share
173
173
173
173
174
173
173
Basic Weighted Avg Shares
4,957
6,785
7,205
7,103
10,300
9,473
12,218
Sales/Revenue/Turnover
37.6
33.53
26.93
28.51
34.95
28.51
35.56
Operating Margin (%)
197
218
251
281
178
240
200
Depreciation Expense
1,384
1,816
1,600
1,638
3,052
2,478
3,586
Net Income, GAAP
26.47
25.34
26.12
25.6
24.85
25.47
25.21
Effective Tax Rate (%)
27.92
26.76
22.21
23.05
29.63
26.16
29.35
Profit Margin (%)
2,269
3,738
4,912
4,997
7,500
7,296
- -
Working Capital
287
133
15
4
165
376
- -
LT Debt
3,398
5,215
6,815
8,452
11,331
13,599
- -
Total Equity
- -
31.89
20.63
16.2
21.54
13.74
- -
Return on Invested Capital (%)
- -
39.98
26.32
21.4
30.53
41.05
969.49
Return on Capital (%)
- -
42.64
26.6
21.45
30.85
42.44
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'25
Mar'25
Jun'26
ST Debt
- -
35
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
165
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
- -
173
- -
Market Capitalization
97,877
152,739
152,365

Working Capital

FRC

•

in mil. unless spec.
Dec'25
Mar'25
Jun'26
Total Current Assets
- -
10,059
- -
Cash, Cash Equivalents & STI
- -
2,848
- -
Accounts Receivable, Net
- -
3,495
- -
Inventories
- -
2,639
- -
Total Current Liabilities
- -
2,559
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
35
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
32.45%
20.02%
Free Cash Flow
- -
-117%
-436.17%
Net Income, GAAP
- -
17.84%
-18.8%
Sales/Revenue/Turnover
- -
15.72%
-8.03%
Total Cash Common Dividend
- -
- -
20%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,795
1,814
1,668
1,827
7,103
2025
1,629
2,083
3,184
3,404
10,300
2026
3,548
1,924
2,347
- -
9,473

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2.54
2.76
1.85
- -
9.44
2025
2.18
3.36
5.71
6.35
17.59
2026
5.26
2.32
3.71
- -
14.29

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
1
2026
- -
- -
- -
- -
1.2
Similar Companies
Lyell Immunopharma, Inc. (LYEL)
Actinogen Medical Limited (ACW.AX)
Tyra Biosciences, Inc. (TYRA)
ESSA Pharma Inc. (EPIX)
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (688336.SS)
Active Biotech AB (ACTI.ST)
Business
Blue Jet Healthcare Limited manufactures pharmaceutical intermediates and active pharmaceutical ingredients for pharmaceutical and healthcare products, with a focus on contrast media intermediates, high-intensity sweeteners including saccharin and its salts, niche pharmaceutical intermediates and APIs targeting anti-infectives, central nervous system, cardiovascular and gastrointestinal treatments, as well as contract development and manufacturing organization services, high-purity solvents, laboratory chemicals and quality assurance testing; the company serves global customers in diagnostic imaging, drug formulation and research across India, Norway, France, the United States, Italy, Sweden, Spain and other international markets. Incorporated in 1968 as Jet Chemicals Private Limited and headquartered in Thane, India, it pioneered saccharin production in India and has expanded through multiple manufacturing facilities including recent sites in Ambernath and commissioning of an advanced contrast media production block in December 2024. In July 2025, its board approved acquisition of 102.48 acres of industrial land in Anakapalli District, Andhra Pradesh, from the Andhra Pradesh Industrial Infrastructure Corporation for a new greenfield manufacturing facility to support long-term capacity expansion aligned with demand in key therapeutic areas.